Background-Catheter ablation of ventricular tachycardia (VT) in nonischemic heart diseases can be challenging, and outcomes across different diseases are incompletely defined. The aim of this study was to describe the outcomes after catheter ablation for nonischemic VT in a large cohort and to compare the electrophysiological findings and outcomes according to the type of underlying disease. Methods and Results-Of the 891 consecutive patients undergoing catheter ablation for ventricular arrhythmias, 226 patients (52±14 years; 79% men) with sustained VT due to nonischemic heart disease were included. The primary end point was all-cause death or heart transplantation. Secondary end points were a composite of death, heart transplantation, or readmission because of VT recurrence within 1 year of discharge. Underlying heart diseases were dilated cardiomyopathy in 119 (53%), valvular heart disease in 34 (15%), arrhythmogenic right ventricular cardiomyopathy in 37 (16%), congenital heart disease in 16 (7%), cardiac sarcoidosis in 13 (6%), and hypertrophic cardiomyopathy in 7 (3%) patients. After ablation, inability to induce any VT was achieved in 55%, and another 20% had inducible VTs modified. Major complications occurred in 5%. Arrhythmogenic right ventricular cardiomyopathy had better outcomes than dilated cardiomyopathy for primary (P=0.002) and secondary end points (P=0.004). Sarcoidosis had worse outcome than dilated cardiomyopathy for secondary end point (P=0.002). At 1 year after the last ablation (a mean of 1.4±0.6 procedures, 1-4), freedom from death, heart transplantation, and readmission for VT recurrence were achieved in 173 (77%) patients. Conclusions-In patients with recurrent VT due to nonischemic heart disease, catheter ablation is often useful, although the outcome varies according to the nature of the underlying heart disease. (Circ Arrhythm Electrophysiol. 2012;5:992-1000.)
V entricular tachycardia (VT) is a marker for increased mortality and reduces quality of life in patients who have implanted defibrillators and heart disease. 1 Evidence that catheter ablation can reduce VT episodes in ischemic heart disease has been reported in case series and several multicenter trials. 2 In patients with nonischemic heart disease, sustained monomorphic VT is also usually due to scar-related reentry, with a minority due to bundle branch reentry or having a focal origin. 3, 4 Catheter ablation outcomes in this population are derived from only a small number of single-center reports, in a relatively small number of patients. Acute success in eliminating inducible VT has varied from 55% to 89% with VT recurrence of 16% to 63%. 2, [5] [6] [7] [8] [9] The aim of this study was to clarify the outcomes of VT ablation for patients with different forms of nonischemic heart disease.
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Methods
Study Subjects
Between January 1999 and July 2010, 891 consecutive patients underwent catheter ablation procedures for ventricular arrhythmias at the Brigham and Women's Hospital. Of these, 226 (25%) had monomorphic sustained VT due to nonischemic heart disease and constitute the study population. The 14 patients who had nonsustained arrhythmias without a history of sustained VT were excluded. Nonischemic heart disease was defined as a myocardial disorder in which there is evidence that the heart muscle is structurally and functionally abnormal, in the absence of significant coronary artery disease. We classified nonischemic heart disease as dilated cardiomyopathy (DCM) when left ventricular ejection fraction (LVEF) was reduced to <0.50 in the absence of one of the following causes of nonischemic heart disease: arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), cardiac sarcoidosis, congenital heart disease, and valvular disease according to previous statements. 10 ARVC was defined based on task force criteria. 11, 12 Cardiac sarcoidosis was diagnosed based on either the pathological identification of noncaseating granuloma without other etiology on cardiac biopsy or examination of the explanted heart or extracardiac sarcoid with clinical findings consistent with cardiac involvement. Patients with prior valvular surgery only were classified as valvular heart disease. Clinical VT, sustained VT, and unmappable VT were defined according to the European Heart Rhythm Association /Heart Rhythm Society Expert Consensus on VT ablation. 2 Each patient gave written informed consent. Studies and data collection were performed according to protocols approved by the Human Research Committee of Brigham and Women's Hospital.
Electrophysiological Study
Ventricular mapping and ablation were performed with salineirrigated or saline-nonirrigated tip catheters as previously described. 13 Electroanatomic mapping was performed with the CARTO mapping system (Biosense Webster, Diamond Bar, CA). Bipolar electrograms were band-pass filtered from 30 to 500 Hz and digitally recorded along with a 12-lead surface ECG using the Cardiolab EP system (General Electric Healthcare, Buckinghamshire, UK). VT was induced with up to 3 extrastimuli and burst pacing from 2 right ventricular sites. Isoproterenol was used if VT was exercise related and usually required in ARVC.
Briefly, hemodynamically tolerated VTs were mapped and ablated during VT. Target sites for ablation were sites with an isolated middiastolic potential, where pacing entrained the VT with concealed fusion and a postpacing interval within 30 ms and a stimulus-to-QRS interval <70% of the VT cycle length.
Electroanatomic mapping for unstable, unmappable VTs was performed during sinus rhythm. Areas of scar were identified based on a bipolar electrogram amplitude of <1.5 mV. 14 Ablation targeted presumptive channels and exits within the low-voltage area as identified from a paced QRS morphology similar to the VT QRS morphology, wide fractionated potentials, or isolated late potentials during sinus or paced rhythm where pacing captured, particularly if the stimulusto-QRS interval was >40 ms, consistent with abnormal conduction. Furthermore, when these sites were adjacent to a valve annulus or region of electrically unexcitable scar, ablation lesions were extended to the unexcitable area in the hope of dividing reentry circuit paths. 15 When possible, we assessed electrograms and entrainment at the initial sites of interest, with initiation of a short episode of VT. This was particularly attempted when initial substrate ablation failed to abolish inducible VT. If no low-voltage area was identified, ablation was attempted at the likely exit region identified as sites with presystolic electrograms during VT or where pace mapping resembled the VT QRS.
Applications were repeated at target areas until unipolar pacing at 10 mA at 2-ms stimulus strength failed to capture. 16 After ablation, VT inducibility was assessed using programmed electric stimulation, with up to 3 extrastimuli from 2 right ventricular (RV) sites with or without isoproterenol infusion. Acute complete success was defined as the absence of any inducible monomorphic VT at the end of the ablation procedure. VT modified was defined as abolition of the clinical or presumed clinical VT, but other VTs remained inducible. Acute ablation failure was defined by the inability to render a clinical or presumed clinical VT no longer inducible. If endocardial ablation failed, percutaneous epicardial mapping and ablation were performed as previously described. 17 The decision to proceed to epicardial mapping and timing of the procedure were left to the attending electrophysiologist. When epicardial ablation was anticipated and the VT was from the RV, initial RV endocardial mapping and ablation were performed with no or limited initial anticoagulation; systemic anticoagulation was administered after a decision was made for endocardial ablation only or after epicardial access was achieved. If epicardial ablation was performed after left ventricular endocardial ablation, heparin was reversed with protamine to achieve an activated clotting time of <200 seconds before attempting pericardial access. If endocardial and epicardial ablation failed, transcoronary ethanol ablation was considered. 18, 19 Renal function was assessed from serum creatinine within 24 hours before the ablation procedure. Renal insufficiency was defined as an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . 20
Follow-Up
The index hospitalization is the first hospitalization for catheter ablation of VT at our institution. The follow-up period started with discharge date of the index hospitalization; 18 patients had >1 ablation procedure during the index hospitalization. Data were collected from a centralized system containing records of all patients treated and followed at Brigham and Women's Hospital and associated Partners Healthcare sites. These records provide a detailed history, including emergency department visits, outpatient clinic visits, data recorded during inpatient care as well as scanned follow-up progress notes from referring physicians monitoring out-of-area patients. In addition, referring cardiologists and primary care physicians were contacted for clinical follow-up of their patients if necessary. All patients had at least 1-year follow-up, and mortality was determined by interrogation of the Social Security Death Index.
The primary end point was all-cause mortality or heart transplantation. The secondary end point was a composite of death, heart transplantation, or readmission because of VT recurrence within 1 year of discharge. An additional secondary end point was VT requiring hospitalization within 1 year of discharge.
Statistical Analysis
Continuous variables are expressed as mean±SD. Nonpaired Student t test or Mann-Whitney U tests were used for continuous variables. Categorical variables, expressed as numbers or percentages, were analyzed using χ 2 tests, unless the expected values in any cells were <5, in which case Fisher exact test was used. Significance was defined as P<0.05. In comparison among types of cardiomyopathies, a P value of 0.01 (equivalent to a Bonferroni-adjusted [5 tests] P value of 0.05) was considered significant. Survival curves were created using the Kaplan-Meier method, and comparisons between groups are based on the logrank test. Multivariable analyses used Cox proportional hazards models to assess predictors of the primary and secondary end points. A 0.10 level of significance was used for variable entry and removal from the stepwise models. The following 6 variables were included as candidates for entry into the stepwise models: age, LVEF, New York Heart Association class ≥III, number of VTs induced, renal insufficiency, and acute ablation failure or not tested after ablation. Statistical analysis was performed using SPSS, version 18.0.0 (SPSS, Chicago, IL).
Results
Patient Characteristics
Patient characteristics are shown in Table 1 . Of 226 patients, underlying heart diseases were classified as DCM in 119 (53%), ARVC in 37 (16%), cardiac sarcoidosis in 13 (6%), HCM in 7 (3%), congenital heart disease in 16 (7%), and valvular heart disease in 34 (15%). A prior ablation had been attempted in 95 (42%) patients (mean of 0.7±0.9 ablations) before referral. Patients had failed a mean of 2.1±1.3 antiarrhythmic drugs. An implantable cardioverter defibrillator had been placed in 185 (82%) patients, a mean of 3.9±3.8 years before ablation, for primary prevention of sudden death in 22 (12%) and for secondary prevention after occurrence of sustained VT/ventricular fibrillation in 163 (88%) patients. Of the 185 patients with prior implantable cardioverter defibrillator implantation, a history of syncope and cardiac arrest was documented in 44 (24%) and 25 (14%) patients, respectively. After catheter ablation, an implantable cardioverter defibrillator was implanted in an additional 18 patients.
All 16 patients with congenital heart disease had a prior surgical repair for their cardiac anomaly: tetralogy of Fallot in 8, ventricular septal defect in 3, transposition of great arteries in 1, double outlet right ventricle in 1, congenital pulmonic valve stenosis in 1, and miscellaneous congenital heart disease in the remaining 2.
VT Ablation
A total of 2.7±2.1 different monomorphic VTs per patient were induced during procedure ( Table 2 ). Bundle branch reentry was recognized in 19 (8%) patients. Low-voltage areas consistent with scar were usually observed in the RV in ARVC and sarcoid patients, but left ventricular scar was detected in 4 of 37 (11%) patients with ARVC and 6 of 13 (46%) patients with sarcoidosis. A transseptal approach was performed in 21 of 159 (13%) patients who required left ventricular access. Epicardial mapping was performed in 60 (27%) patients, and 52 (23%) received epicardial ablation. All 60 patients had prior endocardial mapping and failed endocardial ablation, which had occurred at another institution in 43 patients. In 11 patients, our first attempt was epicardial mapping, but all had a history of prior failed endocardial ablation at another institution. In the remaining 49 patients, we attempted endocardial mapping first but then proceeded to epicardial mapping either at a later procedure (2 patients) or during the same procedure (47 patients). Comparing the first 6 years of the study period to the second 6 years (before versus after January 2005), use of epicardial ablation increased from 13% to 28% of patients, P=0.01. In two thirds of patients, at least 1 induced VT was not mappable. In 63 (28%) patients, only substrate-guided ablation was performed because of hemodynamically unstable VT or inability to reliably induce a clinical or presumptive clinical VT. In 5 patients, transcoronary ethanol ablation was performed after failed radiofrequency catheter ablation. After ablation, no VT was inducible in 124 patients (55%), at least 1 clinical VT was not inducible with other VTs still inducible in 46 patients (20%), and clinical VTs were still inducible in 34 (15%) patients. In the remaining 22 (10%) patients, VT inducibility was not assessed after ablation because it was felt to place the patient at unnecessary risk of hemodynamic or respiratory compromise. During the index hospitalization, 18 patients required a second ablation procedure because of early VT recurrence a median of 2 days after first procedure.
Complications
Major complications, defined as those resulting in permanent injury or requiring intervention for treatment, occurred in 12 (5%) patients during initial hospitalization (Table 3) . Three were clearly related to epicardial access or ablation. Epicardial bleeding >80 mL occurred in 2 cases (bleeding stopped spontaneously or after reversal of heparin anticoagulation; no patient required blood transfusion or surgery). One patient had a small myocardial infarction 2 weeks after epicardial ablation as a result of damage to a right ventricular branch of the right coronary artery that gave rise to the distal portion of the posterior descending coronary artery. 21 Ventricular perforation occurred during endocardial mapping and ablation in 4 patients, of which 3 of them required emergent surgical repair. 22 Two (0.9%) patients died within 30 days, 1 due to uncontrolled VT after failed ablation and the other from sepsis related to surgical pulmonary valve replacement performed after catheter ablation, unrelated to the ablation procedure.
Outcome
Kaplan-Meier curves of the primary and secondary end points are shown in Figure 1 . In multivariable Cox proportional hazards analysis, lower LVEF, New York Heart Association class ≥III, greater number of induced VTs, and renal insufficiency were independent predictors of the primary end point (Table 4 ). Age, lower LVEF, and renal insufficiency were associated with the secondary end point (Table 5 ). Acute ablation failure or no attempted VT induction after ablation was not a predictor of the primary or secondary outcome end point (Tables 4 and 5 ). After excluding the 22 patients who did not have attempted VT induction after ablation, absence of inducible VT after ablation still failed to predict the primary (hazard ratio, 0.926; 95% CI, 0.519-1.650; P=0.794) or secondary end point (hazard Supplement Tables SI and SII) . Secondary end point outcomes for patients who had epicardial ablation, after failing endocardial ablation, were not different from those who had only endocardial ablation (P=0.85) ( Figure 2 ).
Repeat Ablation Procedures
During follow-up after the index hospitalization, repeat ablation procedures were performed in 62 patients. Epicardial ablation, transcoronary ethanol ablation, and surgical ablation were performed in 23, 9, and 3 patients, respectively. Thus, considering all ablation procedures in the 226 patients, epicardial ablation, transcoronary ethanol ablation, and surgical ablation were required in 76 (34%), 17 (8%), and 4 (2%) patients, respectively. Finally, 1 year after the discharge from last ablation procedure (a mean of 1.4±0.6 procedures, 1-4), freedom from death, heart transplantation, and readmission for VT recurrence were achieved in 173 (77%) patients. Kaplan-Meier curves of VT recurrence requiring hospitalization after the index ablation procedure at our center or after the last ablation procedure are shown in Figure 3 .
Differences Among Types of Cardiomyopathies
The DCM group was chosen as a reference group. Comparisons between the DCM and other groups are shown in Tables 1 and 2 . DCM patients had lower LVEF than other groups. Patients with sarcoidosis had a larger number of induced VTs than those with DCM (P<0.01). Ablation abolished all inducible VTs more often in patients with ARVC than in those with DCM (P<0.01). The outcomes after initial hospitalization differed according to the type of nonischemic heart disease (Figures 4  and 5 ). For the primary end point, patients with ARVC had better (P=0.002) and those with congenital heart disease were likely to have better (P=0.04) outcomes than those with DCM. For the secondary end point, patients with ARVC had better outcome than those with DCM (P=0.004). In contrast, patients with cardiac sarcoidosis had worse outcomes than those with DCM (P=0.002). VT recurrences requiring hospitalization differed according to the type of nonischemic heart disease (overall log-rank P=0.04; Figure  6 ). Patients with sarcoidosis had greater risk of VT recurrence requiring hospitalization than those with DCM (P=0.007).
In 119 patients who were classified as DCM, 13 patients had a suspected cause of DCM: doxorubicin-induced in 3, postmyocarditis in 3, postpartum in 2, muscular dystrophy in 3, hemochromatosis in 1, and alcohol-related in 1 patient, respectively. The remaining 106 patients without obvious causes were classified as idiopathic DCM. The outcomes appeared similar between idiopathic DCM and nonidiopathic DCM patients for both primary (P=0.31) and secondary end points (P=0.39). Familial DCM was defined as the presence of DCM in ≥2 family members. In 106 patients with idiopathic DCM, familial DCM was identified in 19 (18%). Outcomes appeared similar between those DCM patients with and without a family history (P=0.27 for primary end point and P=0.71 for secondary end point), but the number of patients is small.
Discussion
Study Results
Our single-center study characterizes the clinical outcomes associated with catheter ablation for VT due to nonischemic heart disease in a large cohort of consecutive patients. To our knowledge, this is the largest study of VT ablation for nonischemic heart disease and the first study to compare the electrophysiological findings and outcomes of catheter ablation procedures for ventricular arrhythmias according to the type of underlying heart disease in this population.
In this cohort of patients with recurrent VT referred for catheter ablation, the prevalence of DCM, ARVC, cardiac sarcoidosis, and HCM are 54%, 15%, 5%, and 3%, respectively. These ratios are in approximate agreement with the estimated prevalence of these diseases in the general population: 1:2500 for DCM, 1:5000 for ARVC, 1:20 000 for cardiac sarcoidosis, but with fewer HCM patients, for whom the prevalence is 1:500. [23] [24] [25] This observation supports the clinical recognition that sustained monomorphic VT is uncommon in HCM. 24, 26 Optimal end points for the acute ablation procedure in patients with nonischemic heart disease remain uncertain. The lack of any inducible VT is generally accepted as a favorable acute result. In ischemic cardiomyopathy, 1 multicenter trial demonstrated that absence of inducible VT was associated with lower recurrence rates, 27 but this finding was not observed in another study. 28 In our series, abolition of all inducible VTs was not an independent predictor of outcome. In nonischemic heart disease, it seems likely that progression of the underlying myocardial disease contributes to the poor correlation between procedural success and clinical outcomes. As in a previous study, we observed that catheter ablation is often able to control incessant VT or electrical storm, which is likely to improve survival and quality of life, although VT may still recur. 29 Epicardial ablation has an important role in patients with nonischemic heart disease. It was used in only 22% of patients of this series, because it was used only if endocardial ablation had previously failed and because our series included patients with congenital and valvular heart disease who have had prior cardiac surgery that often prevents percutaneous epicardial access. Recently, a combined endocardial and epicardial based ablation strategy has been reported to improve results for prevention of recurrent ventricular arrhythmias in patients with ARVC compared with endocardial ablation alone. 30 Although we did not observe better outcomes in patients undergoing epicardial ablation compared with endocardial ablation alone, these findings are due to selection biases because epicardial ablation was usually attempted only if endocardial ablation failed. Thus, successful epicardial ablation did likely improve outcomes for these patients. The observed complication rate is consistent with recent reports. 31, 32 In 26% of the patients, repeat ablation procedures were performed because of VT recurrence. The indication of repeat ablation for recurrent VT has not been defined. In addition to catheter ablation, other approaches, such as transcoronary ethanol ablation and surgical ablation, could be considered in cases with suspected deep intramural substrate and prior cardiac surgery, rendering pericardial access more difficult. 18, 19 We had previously reported that ischemic cardiomyopathy had a 2-fold increased risk of mortality compared with nonischemic heart disease, despite lower VT recurrence. 33 However, the efficacy of VT ablation according to the type of underlying nonischemic heart disease was uncertain. Cardiac sarcoidosis with RV involvement can mimic ARVC. 12, 34 However, the outcome of VT ablation seems worse for cardiac sarcoidosis. Patients with cardiac sarcoidosis also had a larger number of induced VTs, and efficacy of catheter ablation was disappointing in short-term follow-up. Patients with ARVC had greater procedural success and better outcomes after VT ablation than those with DCM.
Congenital heart defects occur in almost 1% of live births. During early childhood, 30% to 50% require surgery. 35 Ventricular scars from ventriculotomy or patches create the substrate for scar-related reentry. VT ablation outcomes were relatively favorable in this group, consistent with a prior report that included many of our patients. 36 
Study Limitations
This study has several limitations. Several forms of nonischemic heart disease causing VT are rare, and sample sizes in subgroups are small, precluding statistical comparisons. However, these data comprise the largest series of such patients treated with catheter ablation for recurrent monomorphic VT. This was a retrospective study, and selection biases undoubtedly determine who is referred for VT ablation. Very ill, end-stage heart failure patients are less likely to be considered for ablation. In the present study, isolated VT recurrences that did not result in hospitalization were not included as an end point. Detection of these events in our referral population can be problematic, and isolated VT recurrences may not preclude good long-term control and clinical benefit.
Conclusions
This relatively large series demonstrates that in patients with recurrent VT due to nonischemic heart disease catheter ablation is often useful and that the outcome of catheter ablation varies according to the nature of the underlying cardiomyopathy.
